News & Events
Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC) (opens in a new tab)
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 CAMBRIDGE, MA, June 29, 2021 – Vedanta Biosciences, a leading clinical-stage microbiome company developi…
International experts join inaugural IBD Advisory Panel (opens in a new tab)
Three key opinion leaders will make much-needed advancements in treatment options for Inflammatory Bowel Disease on new advisory panel. The post International experts join inaugural IBD Advisory Panel appeared first on Microba Life Sciences.…
Advancing microbiome discovery to transform human health (opens in a new tab)
Precise measurement of the gut microbiome empowers new discoveries in research and the development of innovative treatments and diagnostics. The post Advancing microbiome discovery to transform human health appeared first on Microba Life Sciences.…
NEW1000: Tackling health issues at their origin (opens in a new tab)
Using the NEW1000 Family Study, researchers will investigate the role of the microbiome in the developmental origins of health and disease. The post NEW1000: Tackling health issues at their origin appeared first on Microba Life Sciences.…
Seres Therapeutics to Host Virtual Investor Event on June 21, 2021 (opens in a new tab)
Focus on SER-287 and SER-301, Seres’ microbiome therapeutic candidates in development for ulcerative colitis Event to be held ahead of Phase 2b ECO-RESET study clinical induction results anticipated in mid-2021, with additional microbiome pharmacology data expected in H2 2021 CAMBRIDGE, Mass.…
Seres Therapeutics to Present at JMP Securities Life Sciences Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun. 10, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young , Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics , will present at the JMP Securities Life Sciences…
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (opens in a new tab)
– Decreased microbial gastrointestinal diversity in patients undergoing allogeneic HSCT procedures associated with higher mortality and increased incidence of intestinal GvHD – – Data support a cancer-specific microbiome relationship, with correlation identified between microbiome composition and…
Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD) (opens in a new tab)
– SER-155 aims to prevent mortality in immunocompromised patients due to gastrointestinal infections, bacteremia and GvHD – – In collaboration with Memorial Sloan Kettering Cancer Center , Seres will now advance SER-155 into a Phase 1b clinical study – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jun.…
Seres Therapeutics to Present at Upcoming Virtual Investor Conferences (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 25, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that management will present a corporate overview at two upcoming investor conferences: Jefferies Virtual Healthcare Conference at 2:30 p.m.…
Interim Analysis of a Phase 3 Open-Label Study Indicates Safety and Efficacy of RBX2660, an Investigational Live Biotherapeutic, in a “Real-world” Population of Patients with Recurrent Clostridioides Difficile Infection (opens in a new tab)
Colleen Kraft MD1, Sahil Khanna MBBS2, Maha Assi MS MPH3, Paul Feuerstadt MD4, Adam Harvey PhD5, Lindy Bancke PharmD51Emory University, Atlanta, GA, USA; 2Mayo Clinic, Rochester, MN, USA; 3Infectious Disease Consultants, Wichita, KS, USA; 4Gastroenterology Center of Connecticut, Hamden, CT, USA; 5Rebiotix Inc, Rosevill…
Ferring and Rebiotix Present Positive Interim Phase 3 Results from Open-Label Study of Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week® (DDW) (opens in a new tab)
Interim analysis of the Phase 3 PUNCH™ CD3-Open-Label Study (OLS) showed positive efficacy and consistent safety with RBX2660 for up to six months in patients with recurrent Clostridioides difficile (C. difficile) infection, adding to robust evidence of largest clinical development program in microbiome-based therapeut…
Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection (opens in a new tab)
RBX2660 pivotal Phase 3 trial successfully met the primary endpoint; data presented today at Digestive Disease Week® (DDW) RBX2660 is the first microbiota-based live biotherapeutic to demonstrate efficacy as early as first recurrence of Clostridioides difficile (C. difficile) infection RBX2660 Phase 3 data add to the w…
Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021 (opens in a new tab)
– Data validates strength of Seres’ investigational microbiome therapeutics pipeline in potentially addressing unmet treatment needs in recurrent C. difficile infection and ulcerative colitis – – In Phase 3 ECOSPOR III study, SER-109 significantly reduced recurrence rates of C.…
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 20, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Executive Vice President, Chief Financial Officer (CFO) and Head of Business Development, effective June 1, 2021 . Mr.…
Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (opens in a new tab)
– Seres is advancing its microbiome research efforts in oncology to improve patient outcomes following disease treatments – CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 19, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it will present the…
Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 12, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), today announced that management will participate in a panel discussion at the RBC Capital Markets 2021 Global Healthcare Conference on Tuesday, May 18 at 4:15 p.m. ET .…
Seres Therapeutics to Present Key Data on Investigational Microbiome Therapeutics for Recurrent C. difficile Infection and Ulcerative Colitis at the Digestive Disease Week (DDW) Annual Meeting (opens in a new tab)
– Data demonstrates Seres’ leadership in microbiome sciences and therapeutics across multiple diseases – CAMBRIDGE, Mass. –(BUSINESS WIRE)–May 11, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present recent research…
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates (opens in a new tab)
– Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021 – – Ongoing enrollment in SER-109 open label study for recurrent C. difficile infection; On track to achieve 300 subject…
Genetic Analysis Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
Vedanta Biosciences to Present at the SVB Leerink Biopharma Private Company Connect Event (opens in a new tab)
CAMBRIDGE, MA, April 29, 2021 – Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that members of its management team will participate in the SVB Leerink Biopharma…